Maxim Group Lowers AIM ImmunoTech (NYSE:AIM) Price Target to $1.00

AIM ImmunoTech (NYSE:AIM) had its target price lowered by Maxim Group from $2.00 to $1.00 in a report released on Tuesday morning, Benzinga reports. Maxim Group currently has a buy rating on the stock.

Separately, Ascendiant Capital Markets lowered their price target on shares of AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

AIM ImmunoTech Stock Up 3.2 %

AIM ImmunoTech stock opened at $0.27 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.05. The firm has a market cap of $13.84 million, a P/E ratio of -0.42 and a beta of -0.39. The business has a fifty day moving average of $0.30 and a two-hundred day moving average of $0.36. AIM ImmunoTech has a twelve month low of $0.21 and a twelve month high of $0.62.

AIM ImmunoTech (NYSE:AIM) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter. AIM ImmunoTech had a negative return on equity of 269.04% and a negative net margin of 13,952.74%. The company had revenue of $0.05 million for the quarter. On average, analysts forecast that AIM ImmunoTech will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new stake in AIM ImmunoTech Inc. (NYSE:AIM) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned about 7.92% of AIM ImmunoTech as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).